Jacksonville, Florida. – Doctors at the Jacksonville Clinical Research Center say that the technology used to help Pfizer and Moderna develop their COVID-19 vaccine can prevent fatal heart attacks.
Pfizer and Moderna’s COVID-19 vaccine use bioengineered ribonucleic acid to trick the body into resisting the virus. Researchers at the Jacksonville Clinical Research Center say they have now learned to use the same technology to prevent the production of proteins related to fatal heart disease.
Lipoprotein(a), also known as Lp(a), is called the evil twin of low-density lipoprotein (LDL) by doctors, and is often referred to as bad cholesterol. Lp(a) has an additional protein coil that burrows into the artery wall, causing blood clots and inflammation. This increases the chance of suffering from cardiovascular disease and fatal heart attack or stroke.
Dr. Michal Koren is a cardiologist and research director at the Jacksonville Clinical Research Center. His research on bioengineered RNA helped Pfizer and Moderna develop a COVID-1
“Speaking of the COVID-19 vaccine, we are using RNA messaging to boost the signal that exposes the immune system to spike proteins. When we are dealing with cholesterol issues, we are using RNA technology to block information so our body does not This bad chemical substance.” Coron said.
Koren said that people with high levels of Lp(a) may not know that they have Lp(a) because they have not been routinely tested. It is usually found that people in their 30s or 40s with heart disease or stroke have higher Lp(a) levels. In young patients, a combination of extremely high levels of Lp(a) and other cholesterol levels is found. Koren said this protein is usually hereditary.
Colen said: “Half of the family members of indexed cases may also have this problem. Therefore, it is important to understand the genetic relationship of people in the family, especially if someone has a heart attack or stroke when they are young.”
The RNA therapy currently under study involves injections that are very similar to the COVID-19 vaccine. If this method is approved by the U.S. Food and Drug Administration, people with high levels of Lp(a) will no longer need plasma exchange. The process can filter blood like a dialysis machine that filters a dialysis kidney. .
WJXT News4Jax Copyright 2021-All rights reserved.